Product description

Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.

Letrozole API has got Chinese local GMP certificate and CEP certificate in Europe. It also has been approved by US-FDA and Japanese PMDA.
Currently, the sales of Letrozole FDF and API have covered over 10 countries in Europe, America and Asia.
Read more

Specifications

Categories APIs
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Supplied from China

More products from Jiangsu Hengrui Medicine Co., Ltd.

View all our products (78)

Products from other suppliers

Letrozole

Contact information

Address

Telephone

Website

View all contact information